产科药物微生物组学:母体微生物组与药物相互作用的精准药学新前沿
本文综述产科药物微生物组学进展,指出孕期用药常见但疗效个体差异大,传统产科药理聚焦药代动力学而忽视宿主-微生物-药物互作。母体微生物组可能影响药物生物利用度、代谢、疗效与毒性,而抗生素、抗逆转录病毒药、二甲双胍、铁剂和质子泵抑制剂等可重塑母体微生物生态。作者主张将母体微生物组作为治疗反应的重要决定因素纳入精准产科药理。
要点
- 母体微生物组可能影响孕期药物生物利用度、代谢、疗效和毒性。
- 抗生素、抗逆转录病毒药、二甲双胍、铁剂和PPI可重塑母体微生物生态。
- 应将母体微生物组作为治疗反应决定因素纳入精准产科药学。
核心结论
- 产科药理正进入系统生物学时代,母体微生物组应作为治疗反应的重要决定因素加以研究,而非仅视为背景生理变量。
- 将微生物组科学整合入母胎治疗有望改善个体化治疗策略、药物开发和精准产科药理。
研究设计与样本
- 本文为小型综述(mini-review),聚焦产科药物微生物组学的最新进展。
- 综述范围涵盖微生物对药物代谢的调控、妊娠相关微生物重塑、微生物介导的治疗变异性、胎盘与胎儿影响及未来转化应用。
主要发现
- 孕期用药常见,但治疗反应常不可预测,因产科药理历史上聚焦药代动力学变化而较少关注宿主-微生物-药物互作。
- 越来越多的证据表明,母体微生物组可能影响孕期药物生物利用度、代谢、疗效、毒性、免疫反应和胎盘信号传导。
- 产科常用药物包括抗生素、抗逆转录病毒药、二甲双胍、铁剂和质子泵抑制剂,可能重塑母体微生物生态系统并影响母胎健康。
- 妊娠期母体肠道、阴道和口腔微生物群落随孕周演变,胎盘和胎儿暴露于微生物代谢物和微生物相关信号,但无令人信服的稳定定植微生物组证据。
- 新出现的数据提示微生物组成可能影响早产、妊娠期高血压疾病、妊娠期糖尿病、肥胖、胎儿生长、免疫发育和治疗反应性。
临床怎么用
- 临床应考虑母体微生物组对孕期药物疗效和毒性的潜在影响,关注个体化治疗反应差异。
- 使用抗生素、抗逆转录病毒药、二甲双胍、铁剂和质子泵抑制剂时,需注意其对母体微生物生态的重塑及下游母胎健康影响。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Pregnancy is characterized by physiologic, metabolic, immunologic, and microbial adaptation. Medication use during pregnancy is common. Yet, therapeutic response often remains unpredictable because obstetric pharmacology has historically focused on pharmacokinetic changes while paying little attention to host-microbiome-drug interactions. Pharmacomicrobiomics, the study of bidirectional interactions between the microbiome and therapeutic agents, has emerged as an important frontier in precision medicine. Increasing evidence demonstrates that the maternal microbiome may influence drug bioavailability, metabolism, efficacy, toxicity, immune response, and placental signaling during pregnancy. Conversely, medications used in obstetric practice, including antibiotics, antiretrovirals, metformin, iron supplementation, and proton pump inhibitors, may reshape maternal microbial ecosystems with downstream implications for maternal-fetal health. Pregnancy introduces pharmacomicrobiomic complexity because the maternal gut, vaginal, and oral microbial communities evolve across gestation, while the placenta and fetus are exposed to microbial metabolites and microbe-associated signals without convincing evidence of stable resident microbiomes. Emerging data suggest that microbial composition may influence preterm birth, hypertensive disorders of pregnancy, gestational diabetes mellitus, obesity, fetal growth, immune development, and therapeutic responsiveness. This mini-review examines recent advances in obstetric pharmacomicrobiomics with emphasis on microbial regulation of drug metabolism, pregnancy-associated microbial remodeling, microbiome-mediated therapeutic variability, placental and fetal implications, and future translational applications. We propose that obstetric pharmacology is entering a systems biology era in which the maternal microbiome should be investigated as a potentially important determinant of therapeutic response rather than treated solely as a background physiologic variable. Integrating microbiome science into maternal-fetal therapeutics may ultimately improve individualized treatment strategies, drug development, and precision obstetric pharmacology.
引用
- Eke AC. Obstetric Pharmacomicrobiomics. Clin Pharmacol Ther. 2026. PMID: 42852618. doi:10.1002/cpt.70520
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。